目的:系统评价阿戈美拉汀与度洛西汀治疗首发抑郁障碍患者的疗效和安全性的差异。方法:运用中国知网(CNKI)、维普(VIP)、万方、PubMed、Web of Science等数据库进行检索,纳入两种药物治疗首发抑郁障碍的头对头临床随机对照研究,提取疗...目的:系统评价阿戈美拉汀与度洛西汀治疗首发抑郁障碍患者的疗效和安全性的差异。方法:运用中国知网(CNKI)、维普(VIP)、万方、PubMed、Web of Science等数据库进行检索,纳入两种药物治疗首发抑郁障碍的头对头临床随机对照研究,提取疗效和安全性的数据,采用RevMan 5.4进行meta分析。结果:共纳入6篇文章。meta分析结果显示,治疗后阿戈美拉汀组与度洛西汀组HAMD-17评分差异(P<0.05)、总有效率差异(P=0.002)有统计学意义,治愈率差异(P=0.10)、总不良反应发生率差异(P=0.11)无统计学意义。结论:与度洛西汀相比,阿戈美拉汀治疗首发抑郁障碍的安全性相当,疗效具有优势。展开更多
AIM： To investigate the effects of long-term albumin administration on survival, recurrence of ascites and onset of other complications. METHODS： One hundred consecutive patients admitted for first-onset ascites wer...AIM： To investigate the effects of long-term albumin administration on survival, recurrence of ascites and onset of other complications. METHODS： One hundred consecutive patients admitted for first-onset ascites were randomized to receive diuretics plus human albumin 25 g/wk in the first year and 25 g every two wk thereafter （group 1） or diuretics alone （group 2）. The primary endpoint was survival without liver transplantation. Secondary endpoints were recurrence of ascites and occurrence of other complications. RESULTS： Median follow-up was 84 （2-120） mo. Albu- min-treated patients had significantly greater cumulative survival rate （Breslow test= 7.05, P= 0.0078） and lower probability of ascites recurrence （51% versus 94%, P〈0.0001）. Chronic albumin infusion resulted in a mean increase in survival of 16 mo. CONCLUSION： Long-term albumin administration after first-onset ascites significantly improves patients＇ survival and decreases the risk of ascites recurrence.展开更多
文摘目的:系统评价阿戈美拉汀与度洛西汀治疗首发抑郁障碍患者的疗效和安全性的差异。方法:运用中国知网(CNKI)、维普(VIP)、万方、PubMed、Web of Science等数据库进行检索,纳入两种药物治疗首发抑郁障碍的头对头临床随机对照研究,提取疗效和安全性的数据,采用RevMan 5.4进行meta分析。结果:共纳入6篇文章。meta分析结果显示,治疗后阿戈美拉汀组与度洛西汀组HAMD-17评分差异(P<0.05)、总有效率差异(P=0.002)有统计学意义,治愈率差异(P=0.10)、总不良反应发生率差异(P=0.11)无统计学意义。结论:与度洛西汀相比,阿戈美拉汀治疗首发抑郁障碍的安全性相当,疗效具有优势。
基金Supported by grants from the Italian Ministry of Education, University and Research and the University of Florence, Italy
文摘AIM： To investigate the effects of long-term albumin administration on survival, recurrence of ascites and onset of other complications. METHODS： One hundred consecutive patients admitted for first-onset ascites were randomized to receive diuretics plus human albumin 25 g/wk in the first year and 25 g every two wk thereafter （group 1） or diuretics alone （group 2）. The primary endpoint was survival without liver transplantation. Secondary endpoints were recurrence of ascites and occurrence of other complications. RESULTS： Median follow-up was 84 （2-120） mo. Albu- min-treated patients had significantly greater cumulative survival rate （Breslow test= 7.05, P= 0.0078） and lower probability of ascites recurrence （51% versus 94%, P〈0.0001）. Chronic albumin infusion resulted in a mean increase in survival of 16 mo. CONCLUSION： Long-term albumin administration after first-onset ascites significantly improves patients＇ survival and decreases the risk of ascites recurrence.
